{
    "symbol": "FULC",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-10 18:07:05",
    "content": " We provided several important business updates this morning in our press release and 10-K, including additional color on the FTX-6058 full clinical hold, data from the now suspended 12-milligram cohort of the Phase Ib sickle cell disease trial; updated guidance on our cash runway; and changes to our management team. In early January, we shared data from the completed 6-milligram cohort with 10 patients that demonstrated up to 9.5% at fluid HbF increases from baseline, and similar treatment responses to FTX-6058 and subjects on and off background hydroxyurea."
}